VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
How Parkinson’s genetics is transforming drug development
Find out about the latest research into Parkinson’s genetics
3 weeks ago
Survey of young Europeans with neurological conditions launched
The European Federation of Neurological Associations (EFNA) has launched a survey for young Europeans who are living with brain conditions. The survey, which was launched in Brain Awareness Week from 12 to 18 March, aims to gain a better understanding of the issues affecting those with neurological conditions. The research is open to anyone living with such a condition, aged between 18–35 and lives in Europe. The findings from the survey will be announced on World Brain Day 2018 on 22 July – with the information being used to raise awareness among the general public, health professionals and policymakers. Participants are encouraged to share the survey across their networks via email, newsletters and social media. The survey is open until 21 May – to take the survey click here.
Researchers from Kyung Hee University, Seoul, South Korea believe they are closer to finding a cure for Parkinson’s through their research into protein DJ-1. The research, which will be published in US journal ‘Proceedings of the National Academy of Sciences’, has found evidence to suggest the protein impairs nerve cells within the body which relate to the pathogenesis of Parkinson’s disease. Although the protein had previously been linked to the development of Parkinson’s, its exact role remained unknown. Professor Sung Hyun Kim, who led the study, said: “We will research the relationship between synapse function and the expressive actions of animals with Parkinson’s, and establish the related network. If the study goes well, we will be able to infer the cause of Parkinson’s.”
Researchers at the University of Cambridge, UK, have discovered that excess levels of calcium in brain cells may lead to the formation of the toxic clusters that signify Parkinson’s disease. The findings, reported in the journal ‘Nature Communications’, show that calcium can influence the interaction between small membranous structures inside nerve endings, which are important for neuronal signaling in the brain, and alpha-synuclein – the protein associated with Parkinson’s disease. Dr Janin Lautenschläger, the paper’s first author, said: “This is the first time we’ve seen that calcium influences the way alpha-synuclein interacts with synaptic vesicles. We think that alpha-synuclein is almost like a calcium sensor. In the presence of calcium, it changes its structure and how it interacts with its environment, which is likely very important for its normal function.”